Previous 10 | Next 10 |
home / stock / iva / iva articles
Daix (France), Long Island City (New York, United States), January 24, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stag...
Inventiva intends to use the proceeds to fund part of its ongoing pivotal NATiV3 Phase III clinical trial evaluating lanifibranor in patients wit...
The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inven...
Cash and cash equivalents at €43.8 million, short-term deposits at €0.03 million2, and long-term deposit at €5.0 million3 as of September 3...
The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker. Two additional sc...
Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million1, and long-term deposit at €9.3 million2, as of June 30, 2...
Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar...
Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive lice...
Daix (France), Long Island City (New York, United States), August 31, 2023 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharma...
News, Short Squeeze, Breakout and More Instantly...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
Novonix Limited (NVNXF) is expected to report for quarter end 2023-06-30 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Arrival (ARVL) is expected to report for quarter end 2023-06-30 Treasure Global Inc. (TGL) is expected to report $-0.16 for Q4 2023 Manch...